Rusfertide

Three-letter sequence
Asp-Thr-His-Phe-Pro-Cys-Ile-Lys-Phe-Glu-Pro-Arg-Ser-Lys-Gly-Cys-Lys

InChIKey
JRVOBXXOZFTSRF-GVIPULMVSA-N

SMILES
CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)[C@@H](C)CC)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CNC=N5)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N)CCCCN)CO)CCCNC(=N)N)CCC(=O)O)CC6=CC=CC=C6)C(=O)O

• In healthy adults, rusfertide heart repolarization changes closely followed placebo. (Clinical therapeutics, 2025)
• In the polycythemia vera trial, no deaths were reported, including with rusfertide. (Journal of clinical oncology, 2026)
• In healthy subjects receiving rusfertide, no serious side effects occurred. (Clinical pharmacology in drug development, 2025)
• In healthy adults, most adverse events during the rusfertide study were mild. (Drugs in R&D, 2024)
• In patients with polycythemia vera, 85 % had adverse events during rusfertide treatment, mostly Grade 1/2. (Leukemia research, 2025)
• In HFE-related haemochromatosis, 75% had at least one adverse event during rusfertide treatment. (The lancet. Gastroenterology & hepatology, 2023)
• In healthy adults, rusfertide had no clinically relevant effect on heart rate. (Clinical therapeutics, 2025)
• In healthy adults, rusfertide had no clinically relevant effect on the PR heart conduction interval. (Clinical therapeutics, 2025)
• In healthy adults, rusfertide had no clinically relevant effect on the QRS heart conduction interval. (Clinical therapeutics, 2025)
• In healthy adults, predicted heart repolarization change at peak rusfertide concentration was 0.04 ms after placebo correction. (Clinical therapeutics, 2025)
• In healthy subjects receiving rusfertide, injection-site reactions such as redness, hardening and itching were among side effects reported in 2 or more subjects. (Clinical pharmacology in drug development, 2025)
• In healthy subjects receiving rusfertide, 2 or more subjects reported fatigue. (Clinical pharmacology in drug development, 2025)
• In healthy subjects receiving rusfertide, 2 or more subjects reported headache. (Clinical pharmacology in drug development, 2025)
• In healthy subjects receiving rusfertide, safety laboratory tests showed no clinically relevant findings. (Clinical pharmacology in drug development, 2025)
• In healthy subjects receiving rusfertide, vital signs showed no clinically relevant findings. (Clinical pharmacology in drug development, 2025)
• In healthy subjects receiving rusfertide, heart electrical tests showed no clinically relevant findings. (Clinical pharmacology in drug development, 2025)
• In healthy subjects receiving rusfertide, physical examinations showed no clinically relevant findings. (Clinical pharmacology in drug development, 2025)
• In healthy adults, treatment-related injection-site redness occurred in at least 10% of subjects in the rusfertide study. (Drugs in R&D, 2024)
• In healthy adults, treatment-related injection-site itching occurred in at least 10% of subjects in the rusfertide study. (Drugs in R&D, 2024)
• In HFE-related haemochromatosis, 31% had injection site pain during rusfertide treatment. (The lancet. Gastroenterology & hepatology, 2023)
• During rusfertide treatment for haemochromatosis, adverse events were mild or moderate except for severe, pre-existing pancreatic cancer considered unrelated to treatment. (The lancet. Gastroenterology & hepatology, 2023)

The doses that these studies used. They are not recommendations.